### 11791 Federal Register / Vol. 81, No. 44 / Monday, March 7, 2016 / Notices

esubscription.asp to be notified via email of new filings and issuances related to this or other pending projects. For assistance, call 1–866–208–3676 or email FERCOnlineSupport@ferc.gov, for TTY, call (202) 502–8659. A copy is also available for inspection and reproduction at the address in item (h) above. Agencies may obtain copies of the application directly from the applicant.

m. Individuals desiring to be included on the Commission’s mailing list should so indicate by writing to the Secretary of the Commission.

n. Comments, Protests, or Motions to Intervene: Anyone may submit comments, a protest, or a motion to intervene in accordance with the requirements of Rules of Practice and Procedure, 18 CFR 385.210, .211, .214, respectively. In determining the appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission’s Rules may become a party to the proceeding. Any comments, protests, or motions to intervene must be received on or before the specified comment date for the particular application.

o. Filing and Service of Documents: Any filing must (1) bear in all capital letters the title ‘‘COMMENTS’’, ‘‘PROTEST’’, or ‘‘MOTION TO INTERVENE’’ as applicable; (2) set forth in the heading the name of the applicant and the project number of the application to which the filing responds; (3) furnish the name, address, and telephone number of the person commenting, protesting or intervening; and (4) otherwise comply with the requirements of 18 CFR 385.2001 through 385.2005. All comments, motions to intervene, or protests must set forth their evidentiary basis. Any filing made by an intervenor must be accompanied by proof of service on all persons listed in the service list prepared by the Commission in this proceeding, in accordance with 18 CFR

385.2010.

Dated: March 1, 2016. Nathaniel J. Davis, Sr., Deputy Secretary.
[FR Doc. 2016–04961 Filed 3–4–16; 8:45 am]

**BILLING CODE 6717–01–P DEPARTMENT OF ENERGY** 

**National Nuclear Security Administration** 

**Defense Programs Advisory Committee** 

**AGENCY :**  National Nuclear Security Administration, Office of Defense Programs, Department of Energy.

**ACTION :**  Notice of closed meeting.

**SUMMARY :**  This notice announces a closed meeting of the Defense Programs Advisory Committee (DPAC). The Federal Advisory Committee Act (Pub. L. 92–463, 86 Stat. 770) requires that public notice of meetings be announced in the Federal Register. Due to national security considerations, under section 10(d) of the Act and 5 U.S.C. 552b(c), the meeting will be closed to the public and matters to be discussed are exempt from public disclosure under Executive Order 13526 and the Atomic Energy Act of 1954, 42 U.S.C. 2161 and 2162, as amended.

**DATES :**  March 18, 2016, 8:30 a.m. to 5:00
p.m.
**ADDRESSES :**  U.S. Department of Energy, 1000 Independence Ave. SW., Washington, DC 20585.

**FOR FURTHER INFORMATION CONTACT :**  Loretta Martin, Office of RDT&E (NA– 113), National Nuclear Security Administration, U.S. Department of Energy, 1000 Independence Ave. SW., Washington, DC 20585, (202) 586–7996.

**SUPPLEMENTARY INFORMATION :** 

Background: The DPAC provides advice and recommendations to the Deputy Administrator for Defense Programs on the stewardship and maintenance of the Nation’s nuclear deterrent.

Purpose of the Meeting: The purpose of this meeting of the DPAC is to finalize the Committee report to be provided to the National Nuclear Security Administration in response to its charge and to have initial discussion of the next charges to the Committee.

Type of Meeting: In the interest of national security, the meeting will be closed to the public. The Federal Advisory Committee Act, 5 U.S.C. App. 2, section 10(d), and the Federal Advisory Committee Management Regulation, 41 CFR 102–3.155, incorporate by reference the Government in the Sunshine Act, 5 U.S.C. 552b, which, at 552b(c)(1) and (c)(3) permits closure of meetings where restricted data or other classified matters will be discussed. Such data and matters will be discussed at this meeting. Tentative Agenda: Welcome; reading of final draft of report; discussion of report, as necessary; (tentative) acceptance of report; discussion of next charges; conclusion.

Public Participation: There will be no public participation in this closed meeting. Those wishing to provide written comments or statements to the Committee are invited to send them to Loretta Martin at the address listed above.

Minutes: The minutes of the meeting will not be available.

Issued in Washington, DC on March 2,
2016. LaTanya R. Butler, Deputy Committee Management Officer.
[FR Doc. 2016–04975 Filed 3–4–16; 8:45 am]

**BILLING CODE 6450–01–P**

**ENVIRONMENTAL PROTECTION AGENCY** 

**[EPA–HQ–OPP–2008–0844; FRL–9942–69]**

**Imidacloprid Registration Review; Draft Pollinator Ecological Risk**  **Assessment; Extension of Comment Period** 

**AGENCY :**  Environmental Protection Agency (EPA).

**ACTION :**  Notice; extension of comment period.

**SUMMARY :**  EPA issued a notice in the Federal Register of January 15, 2016, opening a comment period for a draft pollinator-only ecological risk assessment for the registration review of imidacloprid. This document extends the comment period for 30 days, from March 15, 2016 to April 14, 2016. This comment period is being extended in response to a number of extension requests from various stakeholders.

**DATES :**  Comments, identified by docket identification (ID) number EPA–HQ– OPP–2008–0844, must be received on or before April 14, 2016.

**ADDRESSES :**  Follow the detailed instructions provided under **ADDRESSES** in the Federal Register document of January 15, 2016 (81 FR 2212) (FRL– 9940–82).

**FOR FURTHER INFORMATION CONTACT :**  Kelly Ballard, Pesticide Re-Evaluation Division (7508P), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave. NW., Washington, DC 20460–0001; telephone number: (703) 305–8126; email address: ballard.kelly@epa.gov.

**SUPPLEMENTARY INFORMATION :** 

This document extends the public comment period established in the


### 11792 Federal Register / Vol. 81, No. 44 / Monday, March 7, 2016 / Notices

1 In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c), 16 CFR 4.9(c). Federal Register document of January 15, 2016 (81 FR 2212) (FRL–9940–82). In that document, EPA opened acomment period for a draft pollinatoronly ecological risk assessment for the registration review of imidacloprid. EPA is hereby extending the comment period, which was set to end on March 15, 2016, to April 14, 2016.

To submit comments, or access the docket, please follow the detailed instructions provided under **ADDRESSES** in the Federal Register document of January 15, 2016. If you have questions, consult the person listed under **FOR**
**FURTHER INFORMATION CONTACT**

.

Authority: 7 U.S.C. 136 et seq. Dated: February 29, 2016. Yu-Ting Guilaran, Director, Pesticide Re-Evaluation, Office of Pesticide Programs.
[FR Doc. 2016–05033 Filed 3–4–16; 8:45 am]

**BILLING CODE 6560–50–P**

**FEDERAL TRADE COMMISSION**

**[File No. 151 0198]**

**Hikma Pharmaceuticals PLC; Analysis To Aid Public Comment** 

**AGENCY :**  Federal Trade Commission.

**ACTION :**  Proposed Consent Agreement.

**SUMMARY :**  The consent agreement in this matter settles alleged violations of federal law prohibiting unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the draft complaint and the terms of the consent orders— embodied in the consent agreement— that would settle these allegations.

**DATES :**  Comments must be received on or before March 29, 2016.

**ADDRESSES :**  Interested parties may file a
comment at https:// ftcpublic.commentworks.com/ftc/ hikmaroxaneconsent online or on paper, by following the instructions in the Request for Comment part of the

**SUPPLEMENTARY INFORMATION** section below. Write ‘‘In the Matter of Hikma Pharmaceuticals PLC,—Consent Agreement; File No. 151–0198’’ on your comment and file your comment online
at https://ftcpublic.commentworks.com/ ftc/hikmaroxaneconsent by following the instructions on the Web-based form. If you prefer to file your comment on paper, write ‘‘In the Matter of Hikma Pharmaceuticals PLC,—Consent Agreement; File No. 151–0198’’ on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC–5610 (Annex D), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex D), Washington, DC 20024.

**FOR FURTHER INFORMATION CONTACT :**  Jacqueline Mendel (202–326–2603), Bureau of Competition, 600 Pennsylvania Avenue NW., Washington, DC 20580.

**SUPPLEMENTARY INFORMATION :**  Pursuant to Section 6(f) of the Federal Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for February 26, 2016), on the World Wide Web, at http:// www.ftc.gov/os/actions.shtm

.

You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before March 29, 2016. Write ‘‘In the Matter of Hikma Pharmaceuticals PLC,—Consent Agreement; File No. 151–0198’’ on your comment. Your comment—including your name and your state—will be placed on the public record of this proceeding, including, to the extent practicable, on the public Commission Web site, at http:// www.ftc.gov/os/publiccomments.shtm

. As a matter of discretion, the Commission tries to remove individuals’ home contact information from comments before placing them on the Commission Web site.

Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, like anyone’s Social Security number, date of birth, driver’s license number or other state identification number or foreign country equivalent, passport number, financial account number, or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, like medical records or other individually identifiable health information. In addition, do not include any ‘‘[t]rade secret or any commercial or financial information which . . . is privileged or confidential,’’ as discussed in Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2). In particular, do not include competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer

names.

If you want the Commission to give your comment confidential treatment, you must file it in paper form, with a request for confidential treatment, and you have to follow the procedure explained in FTC Rule 4.9(c), 16 CFR 4.9(c). 1 Your comment will be kept confidential only if the FTC General Counsel, in his or her sole discretion, grants your request in accordance with the law and the public interest.

Postal mail addressed to the Commission is subject to delay due to heightened security screening. As a result, we encourage you to submit your comments online. To make sure that the Commission considers your online comment, you must file it at https:// ftcpublic.commentworks.com/ftc/ hikmaroxaneconsent by following the instructions on the Web-based form. If this Notice appears at http:// www.regulations.gov/#!home, you also may file a comment through that Web site.

If you file your comment on paper, write ‘‘In the Matter of Hikma Pharmaceuticals PLC,—Consent Agreement; File No. 151–0198’’ on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC–5610 (Annex D), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex D), Washington, DC 20024. If possible, submit your paper comment to the Commission by courier or overnight service.

Visit the Commission Web site at http://www.ftc.gov to read this Notice and the news release describing it. The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before March 29, 2016. You can find